(Michael Sjபெberg / Bloomberg)
(Bloomberg) – The UK plans to offer the AstraZeneca vaccine as an alternative to the Covit-19 vaccine for people under the age of 40 due to the risk of thrombosis cases, which has so far affected a small proportion of those who have been vaccinated. The person who knows the matter well.
The person said the decision could be announced from this Friday after the recommendation of the Joint Vaccine and Immunization Commission.
Authorities are preparing to launch an immunization program for children under the age of 40. Individuals over the age of 40 were instructed to seek an appointment for the vaccine this week.
The Astrogeneca vaccine is the flagship of the UK program to date. With the new strategy, depending on the offer, people under the age of 40 will receive vaccines from Pfizer-Bioentech or Moderna, the only two vaccines currently allowed for use in the UK.
The decision comes a month after the UK decided to offer the Astrogene vaccine as an alternative to those under 30, as officials described it as a “very rare” case of thrombosis. During that time, 79 cases were recorded and 19 deaths were managed at a rate of over 20 million.
At the same time, the company said it was “working to understand individual events, epidemiology and possible mechanisms by which these very rare events can be explained.”
As of April 28, 242 thrombosis cases have been reported with 49 deaths, after approximately 28.5 million doses of the AstraZeneca vaccine.
Do you want to live on income? These 3 assets can create a powerful portfolio. Check out the free course Mastering Passive Income.
Related
Henry Blackwell is a contributor at Mediarunsearch.co.uk, covering a wide range of topics including news, politics, business, technology, sport, entertainment, and lifestyle. He focuses on delivering clear, balanced reporting and useful information that helps readers stay informed about current events and emerging developments. His work highlights stories that matter to everyday audiences, with an emphasis on accuracy, relevance, and accessible journalism.